keywords: genelabs biotechnology lupus ineffective technologies
text: Genelabs plunges on failed study BOSTON (CBS.MW) -- Shares of Genelabs Technologies Inc. plummeted early Tuesday after the biotechnology firm announced that its lupus drug Prestara has proven ineffective in a Phase III clinical study.